Beyond Depression: Use of rTMS for Difficult-to-Treat Neuropsychiatric Illness

Grand Rounds

Event Info

Breadcrumb

  1. Events
  2. Grand Rounds
  3. Beyond Depression: Use of rTMS for Difficult-to-Treat N...

Beyond Depression: Use of rTMS for Difficult-to-Treat Neuropsychiatric Illness


29September

Event Info
Category Date and Time
  • Wednesday, September 29, 2021
  • 01:00 PM - 02:00 PM
Topic and Speaker
  • Beyond Depression: Use of rTMS for Difficult-to-Treat Neuropsychiatric Illness
  • Andrew F. Leuchter MD
    • Distinguished Professor and Executive Vice Chair
    • Department of Psychiatry and Biobehavioral Sciences
    • Associate Director, Semel Institute for Neuroscience and Human Behavior
    • Director, TMS Clinical and Research Service
    • Director, Neuromodulation Division
    • David Geffen School of Medicine at UCLA
    Andrew F. Leuchter

Location
  • Online - via Zoom
Event Coordinator
  • Alexandria C. Springer
  • (312) 413-0997
  • aspring1 [at] uic.edu
Video Recording
Event Details

Register in advance for this meeting:
https://uic.zoom.us/meeting/register/tZ0kdeCpqTkrEtdPHm2FG6Dl5rqwWAjrV48n
After registering, you will receive a confirmation email containing information about joining the meeting.

A link to access CME evaluations will be sent to attendees after the presentation. (Note: Completed evaluations are required to obtain CME credit)

Andrew F. Leuchter, MD, is a Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior, Executive Vice Chair of the Department of Psychiatry and Biobehavioral Sciences, and Associate Director of the Semel Institute. He also is Director of the Neuromodulation Division at the Semel Institute. Dr. Leuchter is a graduate of Stanford University and the Baylor College of Medicine who joined the UCLA faculty in 1986. An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country, which performs more than 6,000 treatments each year for patients with depression, pain, and other neuropsychiatric illness. He performs research to enhance TMS treatment effectiveness, as well as clinical trials to improve treatment of depression, Post-Traumatic Stress Disorder (PTSD), and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and predict which treatments are most likely to benefit individual patients.


Audience:

Psychiatrists, Neurologists, and other affiliated professionals interested in mental health

Purpose:

To provide current information on research, treatment, and policy issues relating to psychiatry and its adjunct fields

Instructional level:

Advanced

Objectives:

  1. Discuss the mechanism of action of repetitive Transcranial Magnetic Stimulation (rTMS)
  2. Review advanced approaches to rTMS for treatment-resistant depression
  3. Present data on the efficacy of rTMS for treatment of MDD, OCD, tinnitus, and chronic pain

The University of Illinois at Chicago (UIC) College of Medicine is accredited by the Accreditation Council for Continuing Medical Education ACCME) to provide continuing medical education for physicians.

The University of Illinois at Chicago (UIC) College of Medicine designates this live activity for a maximum of 1credit AMA PRA Category 1 credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Continuing Education Units (1) will be available for Social Workers and affiliated reciprocal agencies. Illinois Board License number 159-000112.

The Department of Psychiatry at the University of Illinois at Chicago is approved by the American Psychological Association to sponsor continuing education for psychologists.  The Department of Psychiatry at the University of Illinois at Chicago maintains responsibility for this program and its content. This event is 1 credit hour continuing education.

No member of the planning committee for this activity have reported a relevant relationship with a commercial interest.  There is no conflict of interest and nothing to disclose.

Dr. Andrew Leuchter has disclosed receiving grant support from NeuroSigma; providing consulting service to elminda, Neosync, and EFovea; and being the Co-Founder and Chief Scientific Officer of Brain Biomarker Analytics.